BioScale, Inc. today announced that the company is changing its name to ProterixBio, Inc. The name change reflects a new strategic direction centered on high value clinical apps including diagnostics products and disease management services. ProterixBio’s initial focus is on pulmonary diseases such as COPD (chronic obstructive pulmonary disease), which affects more than 12 million Americans.The company has made significant progress toward these new goals, including:- Recruitment of a
Read More
- Skip to main content
- Skip to secondary menu
- Skip to primary sidebar
- Skip to secondary sidebar
- Skip to footer
Footer
